Blinatumomab with or without nivolumab for first relapse ALL
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Immune system & allergy, Infections clinical trials.
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 1 to under 31 when you start the study.
- You must have first relapse of CD19-positive B-ALL (the leukemia cells still show CD19).
- Your relapse must be in certain places, like bone marrow, the brain/spinal fluid (CNS) or testicles, with specific exclusions.
- You must be able to do daily activities fairly well (ECOG 0–2).
- You must have fully recovered from side effects of prior cancer treatments and have not had a bone marrow transplant before.
- Your kidneys and heart must work well enough for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Hear when a new Down Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.